1. Lindenbach BD, Rice CM. The ins and outs of hepatitis C virus entry and assembly. Nat Rev Microbiol. 2013;11(10): 688-700.
2. Freedman H, Logan MR, Law JL, Houghton M. Structure and function of the hepatitis C virus envelope glycoproteins E1 and E2: antiviral and vaccine targets. ACS Infect Dis. 2016; 2(11): 749-762.
3. Shimizu YK, Hijikata M, Iwamoto A, Alter HJ, Purcell RH, Yoshikura H. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J Virol. 1994; 68(3): 1494-1500.
4. Law M, Maruyama T, Lewis J, Giang E, Tarr AW, Stamataki Z, et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med. 2008; 14(1): 25-27.
5. Perotti M, Mancini N, Diotti RA, Tarr AW, Ball JK, Owsianka A, et al. Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein. J Virol. 2008; 82(2): 1047-1052.
6. Keck ZY, Saha A, Xia J, Wang Y, Lau P, Krey T, et al. Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations. J Virol. 2011; 85(20): 10451-10463.
7. Keck ZY, Xia J, Cai Z, Li TK, Owsianka AM, Patel AH, et al. Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions. J Virol. 2007; 81(2): 1043-1047.
8. Owsianka AM, Tarr AW, Keck ZY, Li TK, Witteveldt J, Adair R, et al. Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. J Gen Virol. 2008; 89(Pt 3): 653-659.
9. Keck ZY, Sung VM, Perkins S, Rowe J, Paul S, Liang TJ, et al. Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity. J Virol. 2004; 78(13): 7257-7263.
10. Kong L, Kadam RU, Giang E, Ruwona TB, Nieusma T, Culhane JC, et al. Structure of hepatitis C virus envelope glycoprotein E1 antigenic site 314-324 in complex with antibody IGH526. J Mol Biol. 2015; 427(16): 2617-2628.
11. Keck ZY, Xia J, Wang Y, Wang W, Krey T, Prentoe J, Carlsen T, Li AY, Patel AH, Lemon SM, Bukh J, Rey FA, Foung SK. Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. PLoS Pathog. 2012; 8(4): e1002653.
12. Potter JA, Owsianka AM, Jeffery N, Matthews DJ, Keck ZY, Lau P, et al. Toward a hepatitis C virus vaccine: the structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody. J Virol. 2012; 86(23): 12923-12932.
13. Sautto G, Tarr AW, Mancini N, Clementi M. Structural and antigenic definition of hepatitis C virus E2 glycoprotein epitopes targeted by monoclonal antibodies. Clin Dev Immunol. 2013; 2013: 450963.
14. Bhardwaj VK, Singh R, Sharma J, Das P, Purohit R. Structural based study to identify new potential inhibitors for dual specificity tyrosine-phosphorylation- regulated kinase. Comput Methods Programs Biomed. 2020; 194: 105494.
15. Gopalakrishnan C, Kamaraj B, Purohit R. Mutations in microRNA binding sites of CEP genes involved in cancer. Cell Biochem Biophys. 2014; 70(3): 1933-1942.
16. Singh R, Bhardwaj VK, Purohit R. Potential of turmeric-derivedcompounds against RNA-dependent RNA polymerase of SARSCoV-2: an in-silico approach. Comput Biol Med. 2021; 139: 104965.
17. Tanwar G, Purohit R. Gain of native conformation of Aurora A S155R mutant by small molecules. J Cell Biochem. 2019; 120(7): 11104-11114.
18. Rajendran V, Gopalakrishnan C, Purohit R. Impact of point mutation P29S in RAC1 on tumorigenesis. Tumour Biol. 2016; 37(11): 15293-15304.
19. Rajendran V, Gopalakrishnan C, Sethumadhavan R. Pathological role of a point mutation (T315I) in BCR-ABL1 protein-A computational insight. J Cell Biochem. 2018; 119(1): 918-925.
20. De Berardinis P, Sartorius R, Fanutti C, Perham RN, Del Pozzo G, Guardiola J. Phage display of peptide epitopes from HIV-1 elicits strong cytolytic responses. Nat Biotechnol. 2000; 18(8): 873-876.
21. Li W, Li L, Sun T, He Y, Liu G, Xiao Z, et al. Spike protein-based epitopes predicted against SARS-CoV-2 through literature mining. Med Nov Technol Devices. 2020; 8: 100048.
22. Bozovičar K, Bratkovič T. Evolving a peptide: library platforms and diversification strategies. Int J Mol Sci. 2019; 21(1): 215.
23. Mink MA, Benichou S, Madaule P, Tiollais P, Prince AM, Inchauspe G. Characterization and mapping of a B-cell immunogenic domain in hepatitis C virus E2 glycoprotein using a yeast peptide library. Virology. 1994; 200(1): 246-255.
24. Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: molecular evolutionary genetics analysis across computing platforms. Mol Biol Evol. 2018; 35(6): 1547-1549.
25. Yechezkel I, Law M, Tzarum N. From structural studies to HCV vaccine design. Viruses. 2021; 13(5): 833.
26. Land H, Humble MS. YASARA: a tool to obtain structural guidance in biocatalytic investigations. Methods Mol Biol. 2018; 1685: 43-67.
27. Vita R, Mahajan S, Overton JA, Dhanda SK, Martini S, Cantrell JR, et al. The immune epitope database (IEDB): 2018 update. Nucleic Acids Res. 2019; 47(D1): D339-D343.
28. Hallen MA, Martin JW, Ojewole A, Jou JD, Lowegard AU, Frenkel MS, et al. OSPREY 3.0: open-source protein redesign for you, with powerful new features. J Comput Chem. 2018; 39(30): 2494-2507.
29. Bazmara S, Shadmani M, Ghasemnejad A, Aghazadeh H, Pooshang Bagheri K. In silico rational design of a novel tetraepitope tetanus vaccine with complete population coverage using developed immunoinformatics and surface epitope mapping approaches. Med Hypotheses. 2019; 130: 109267.
30. Pierce BG, Keck ZY, Lau P, Fauvelle C, Gowthaman R, Baumert TF, et al. Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: implications for vaccine design. Proc Natl Acad Sci USA. 2016; 113(45): E6946-E6954.
31. Kong L, Giang E, Nieusma T, Kadam RU, Cogburn KE, Hua Y, et al. Hepatitis C virus E2 envelope glycoprotein core structure. Science. 2013; 342(6162): 1090-1094.
32. Kong L, Giang E, Robbins JB, Stanfield RL, Burton DR, Wilson IA, et al. Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1. Proc Natl Acad Sci USA. 2012; 109(24): 9499-9504.
33. Keck ZY, Olson O, Gal-Tanamy M, Xia J, Patel AH, Dreux M, et al. A point mutation leading to hepatitis C virus escape from neutralization by a monoclonal antibody to a conserved conformational epitope. J Virol. 2008; 82(12): 6067-6072.
34. El-Diwany R, Cohen VJ, Mankowski MC, Wasilewski LN, Brady JK, Snider AE, et al. Extra-epitopic hepatitis C virus polymorphisms confer resistance to broadly neutralizing antibodies by modulating binding to scavenger receptor B1. PLoS Pathog. 2017; 13(2): e1006235.
35. Rodrigo C, Walker MR, Leung P, Eltahla AA, Grebely J, Dore GJ, et al. Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection. Infect Genet Evol. 2017; 49: 88-96.
36. Keck Zy, Angus AG, Wang W, Lau P, Wang Y, Gatherer D, et al. Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412-423. PLoS Pathogens. 2014; 10(8): e1004297.